When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
PRVB - Provention Bio down 9% premarket on PRV-6527 flop
Provention Bio Inc.
A Phase 2a clinical trial, PRINCE, evaluating Provention Bio's (NASDAQ:PRVB) PRV-6527, a small molecule oral inhibitor of CSF-1R in-licensed from Janssen Pharmaceutical Company, in 93 patients with moderate-to-severe Crohn's disease who were either naïve to biologic therapy or failed to adequately respond to at least one prior biologic drug showed a treatment effect but did not sufficiently separate from placebo.
More news on: Provention Bio, Inc., Healthcare stocks news, Stocks on the move,